Pidilizumab in the treatment of diffuse large B-cell lymphoma, PMID: 25056108
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma, PMID: 25823918
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review, PMID: 26654227
Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma, PMID: 29143272
Utilisation des inhibiteurs de PD-1 dans les hémopathies lymphoïdes, PMID: 28057180
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, PMID: 24332512
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial, PMID: 24127452
Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1, PMID: 33559526
Anti-PD-1 therapy in melanoma, PMID: 25965365
Regulatory B cells in anti-tumor immunity, PMID: 25999597
[Side effects of Modern Immunotherapy and How to Solve Them in the Clinics], PMID: 26647898
Emerging antibodies for the treatment of multiple myeloma, PMID: 27195659
Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma, PMID: 26248256
[Breaking immune tolerance in cancer], PMID: 25609492
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy, PMID: 24917416
Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis, PMID: 26394770
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future, PMID: 28123899
Immune checkpoint blockade: Releasing the brake towards hematological malignancies, PMID: 26699946
Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas, PMID: 26581237
Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity, PMID: 25927868
[Advances in management of follicular lymphoma], PMID: 25297758
Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions, PMID: 24892254
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis, PMID: 26775673
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies, PMID: 26432723
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises, PMID: 25586601
Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors, PMID: 29370105
The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines, PMID: 26986169
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis, PMID: 26513491
Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence, PMID: 31432278
Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma, PMID: 24771328
Anti-PD1 antibody: a new approach to treatment of lymphomas, PMID: 24332517
Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma, PMID: 26155425
Supraorbital Keyhole Approach to the Sella and Anterior Skull Base via a Forehead Wrinkle Incision, PMID: 28989048
Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma, PMID: 24127445
Rupture or traumatic dislocation of cranial suture on infants, involvement of the lambdoidal accessory bones (Wormian bones): case presentation and analysis, PMID: 31037423
Computationally-obtained structural insights into the molecular interactions between Pidilizumab and binding partners DLL1 and PD-1., PMID:33559526
Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence., PMID:31432278
Rupture or traumatic dislocation of cranial suture on infants, involvement of the lambdoidal accessory bones (Wormian bones): case presentation and analysis., PMID:31037423
Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors., PMID:29370105
Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma., PMID:29143272
Supraorbital Keyhole Approach to the Sella and Anterior Skull Base via a Forehead Wrinkle Incision., PMID:28989048
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future., PMID:28123899
[Not Available]., PMID:28057180
Emerging antibodies for the treatment of multiple myeloma., PMID:27195659
The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines., PMID:26986169
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis., PMID:26775673
Immune checkpoint blockade: Releasing the brake towards hematological malignancies., PMID:26699946
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review., PMID:26654227
[Side effects of Modern Immunotherapy and How to Solve Them in the Clinics]., PMID:26647898
Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas., PMID:26581237
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis., PMID:26513491
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies., PMID:26432723
Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis., PMID:26394770
Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma., PMID:26248256
Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma., PMID:26155425
Regulatory B cells in anti-tumor immunity., PMID:25999597
Anti-PD-1 therapy in melanoma., PMID:25965365
Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity., PMID:25927868
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma., PMID:25823918
[Breaking immune tolerance in cancer]., PMID:25609492
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises., PMID:25586601
[Advances in management of follicular lymphoma]., PMID:25297758
Pidilizumab in the treatment of diffuse large B-cell lymphoma., PMID:25056108
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy., PMID:24917416
Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions., PMID:24892254
Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma., PMID:24771328
Anti-PD1 antibody: a new approach to treatment of lymphomas., PMID:24332517
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial., PMID:24332512
Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial., PMID:24127452
Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma., PMID:24127445
For research use only. Not for human or drug use.
